Post by lakers on Feb 5, 2016 16:38:12 GMT -5
Jeffrey Herz
President and CEO at Algomedix
Greater Seattle AreaBiotechnology
Previous
Omeros Corporation
Education
University of California, San Diego - School of Medicine
Background
Summary
Accomplished innovative pharmacologist, Research Program Director and Project Leader with 19 years experience in directing all phases of non-clinical pharmaceutical research and development. Experienced in moving new drugs though all phases of R&D, from discovery research through entry into clinical trials. Responsible for scientific oversight, execution, analysis and reporting of multiple concurrent in vitro, ex vivo and in vivo studies conducted in-house, outsourced to CROs and academic collaborations. Inventor of 56 issued and allowed pharmaceutical technology patents in multiple therapeutic areas. Goal oriented, attention to detail and proven ability to work in an interdisciplinary team. Trusted by senior management to provide scientific leadership and strategic advice for company critical efforts.
Specialties:Molecular Pharmacology, Assay Development, HTS, Animal Models and Pharmacology, Physiology, Integrated Drug Development,
Patents, Intellectual Property Management
Experience
President and CEO
Algomedix
January 2010 – Present (6 years 2 months)
an emerging pharmaceutical company focused on developing first-in-class medicines to treat chronic pain
Director of Discovery Research
Omeros Corporation
April 1998 – August 2009 (11 years 5 months)
• Integrated discovery and development research with pharmacological goals for therapeutic programs resulting in the filing of three INDs and the initiation of 3 clinical programs. The most advanced product for the company is now in Phase III clinical trials.
• Led research and discovery programs for perioperative local delivery of small molecules for multiple therapeutic applications, including arthroscopic, urological and ocular, creating a pipeline of pharmaceutical products. Molecular targets included GPCRs, enzymes, kinases and ion channels.
• Designed and executed appropriate research strategies for internal and external pharmacology activities in support of the company’s internal and collaborative drug discovery and development efforts
• Managed and conducted in vitro, ex vivo and in vivo pharmacological studies to support progression of lead molecules to drug candidates and supported ongoing clinical development of 3 products
• Prepared technical reports, pharmacology and toxicology sections for company’s FDA filings and worked closely with formulation, regulatory and clinical departments to develop final product specifications
• Responsible for implementing and managing ex vivo and in vivo preclinical pharmacology studies to establish proof of concept for drug candidates in a wide variety of animal models based upon human surgical procedures.
• Designed and managed external research studies with academic partners at major universities
• Inventor of 56 issued and allowed patents (15 U.S. and 41 foreign) and 60 pending patents which established core technology for company in a diverse therapeutic areas, including urology, ocular and osteoarthritis and cartilage repair.
• conducted due diligence activities necessary to evaluate technology licensing
• author and coauthor of 35 scientific papers, reviews and 27 abstracts
Richard J. Klein
CFO and Investor
I met Jeff during our time together at Omeros and our professional relationship has continued through subsequent ventures. Jeff's scientific and technical expertise stands on a strong foundation from a solid education to significant accomplishments in the research and development of novel drugs and technologies in the biotech/pharma industry.
I have had the pleasure to further collaborate with Jeff as he has embarked on the challenges and opportunities of his new and exciting venture, Algomedix. Jeff has done an remarkable job of laying the groundwork for a very promising biotechnology enterprise. Jeff is driven, focused and creative, and he operates with a high level of integrity.less
February 2, 2015, Richard J. worked with Jeffrey at Omeros Corporation
Susanne Wang
Senior Medical Director, Neuromuscular Clinical Science
I worked with Jeff for 9 months at Omeros and we have continued our scientific discussions until today. Jeff has broad knowledge in Pharmacology, and I see him as a pioneer in drug discovery research. He is a critical thinker and a practical doer. Jeff holds several patents and he has many great ideas for research and discovery. I highly recommend Jeff’s work at Omeros.
November 3, 2008, Susanne worked directly with Jeffrey at Omeros Corporation
Algomedix is an emerging biopharmaceutical company focused on developing novel therapeutics for the treatment of chronic pain and inflammation. More than 100 million Americans suffer from chronic pain. Existing therapeutics for chronic pain based upon opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are inadequate in addressing patient and physician needs, as well as a regulatory issue for the FDA. Use of these existing medicines presents significant safety, tolerability, abuse and addiction concerns that limit use. A major unmet medical need is an effective therapeutic for chronic pain that is devoid of both addictive potential and abuse liability. Algomedix has discovered and is developing a novel non-opiod drug that solves these problems. The estimated market for this potential first-in-class drug in the primary indication is estimated > $1 billion.
Our Approach
Our approach to discovery and development of a first-in-class analgesic is based upon a novel approach to pain relief: blocking pain at its source in the peripheral nervous system. In addition, the new drug acts as an analgesic by a defined mechanism of action. The target for the Algomedix drug is located on the endings of sensory nerves that transmit the sensations of pain and hyperalgesia in response to inflammation and injury. Our rational drug discovery approach has resulted in the identification of numerous novel agonists and antagonists. The Algomedix lead compound is protectable from an independent IP position, characterized by drug-like properties and acts by a defined mechanism of action. The next-generation therapeutic we are developing has many factors correlated with commercial success and will be highly differentiated from existing analgesics at launch.
Contact Us
Algomedix, Inc.
16212 Bothell-Everett Highway
Suite F280
Mill Creek, WA 98012
Direct: 425-379-7900
[Called this number. A man picked up the phone saying this was Algomedix]
www.algomedix.com/home.html
President and CEO at Algomedix
Greater Seattle AreaBiotechnology
Previous
Omeros Corporation
Education
University of California, San Diego - School of Medicine
Background
Summary
Accomplished innovative pharmacologist, Research Program Director and Project Leader with 19 years experience in directing all phases of non-clinical pharmaceutical research and development. Experienced in moving new drugs though all phases of R&D, from discovery research through entry into clinical trials. Responsible for scientific oversight, execution, analysis and reporting of multiple concurrent in vitro, ex vivo and in vivo studies conducted in-house, outsourced to CROs and academic collaborations. Inventor of 56 issued and allowed pharmaceutical technology patents in multiple therapeutic areas. Goal oriented, attention to detail and proven ability to work in an interdisciplinary team. Trusted by senior management to provide scientific leadership and strategic advice for company critical efforts.
Specialties:Molecular Pharmacology, Assay Development, HTS, Animal Models and Pharmacology, Physiology, Integrated Drug Development,
Patents, Intellectual Property Management
Experience
President and CEO
Algomedix
January 2010 – Present (6 years 2 months)
an emerging pharmaceutical company focused on developing first-in-class medicines to treat chronic pain
Director of Discovery Research
Omeros Corporation
April 1998 – August 2009 (11 years 5 months)
• Integrated discovery and development research with pharmacological goals for therapeutic programs resulting in the filing of three INDs and the initiation of 3 clinical programs. The most advanced product for the company is now in Phase III clinical trials.
• Led research and discovery programs for perioperative local delivery of small molecules for multiple therapeutic applications, including arthroscopic, urological and ocular, creating a pipeline of pharmaceutical products. Molecular targets included GPCRs, enzymes, kinases and ion channels.
• Designed and executed appropriate research strategies for internal and external pharmacology activities in support of the company’s internal and collaborative drug discovery and development efforts
• Managed and conducted in vitro, ex vivo and in vivo pharmacological studies to support progression of lead molecules to drug candidates and supported ongoing clinical development of 3 products
• Prepared technical reports, pharmacology and toxicology sections for company’s FDA filings and worked closely with formulation, regulatory and clinical departments to develop final product specifications
• Responsible for implementing and managing ex vivo and in vivo preclinical pharmacology studies to establish proof of concept for drug candidates in a wide variety of animal models based upon human surgical procedures.
• Designed and managed external research studies with academic partners at major universities
• Inventor of 56 issued and allowed patents (15 U.S. and 41 foreign) and 60 pending patents which established core technology for company in a diverse therapeutic areas, including urology, ocular and osteoarthritis and cartilage repair.
• conducted due diligence activities necessary to evaluate technology licensing
• author and coauthor of 35 scientific papers, reviews and 27 abstracts
Richard J. Klein
CFO and Investor
I met Jeff during our time together at Omeros and our professional relationship has continued through subsequent ventures. Jeff's scientific and technical expertise stands on a strong foundation from a solid education to significant accomplishments in the research and development of novel drugs and technologies in the biotech/pharma industry.
I have had the pleasure to further collaborate with Jeff as he has embarked on the challenges and opportunities of his new and exciting venture, Algomedix. Jeff has done an remarkable job of laying the groundwork for a very promising biotechnology enterprise. Jeff is driven, focused and creative, and he operates with a high level of integrity.less
February 2, 2015, Richard J. worked with Jeffrey at Omeros Corporation
Susanne Wang
Senior Medical Director, Neuromuscular Clinical Science
I worked with Jeff for 9 months at Omeros and we have continued our scientific discussions until today. Jeff has broad knowledge in Pharmacology, and I see him as a pioneer in drug discovery research. He is a critical thinker and a practical doer. Jeff holds several patents and he has many great ideas for research and discovery. I highly recommend Jeff’s work at Omeros.
November 3, 2008, Susanne worked directly with Jeffrey at Omeros Corporation
Algomedix is an emerging biopharmaceutical company focused on developing novel therapeutics for the treatment of chronic pain and inflammation. More than 100 million Americans suffer from chronic pain. Existing therapeutics for chronic pain based upon opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are inadequate in addressing patient and physician needs, as well as a regulatory issue for the FDA. Use of these existing medicines presents significant safety, tolerability, abuse and addiction concerns that limit use. A major unmet medical need is an effective therapeutic for chronic pain that is devoid of both addictive potential and abuse liability. Algomedix has discovered and is developing a novel non-opiod drug that solves these problems. The estimated market for this potential first-in-class drug in the primary indication is estimated > $1 billion.
Our Approach
Our approach to discovery and development of a first-in-class analgesic is based upon a novel approach to pain relief: blocking pain at its source in the peripheral nervous system. In addition, the new drug acts as an analgesic by a defined mechanism of action. The target for the Algomedix drug is located on the endings of sensory nerves that transmit the sensations of pain and hyperalgesia in response to inflammation and injury. Our rational drug discovery approach has resulted in the identification of numerous novel agonists and antagonists. The Algomedix lead compound is protectable from an independent IP position, characterized by drug-like properties and acts by a defined mechanism of action. The next-generation therapeutic we are developing has many factors correlated with commercial success and will be highly differentiated from existing analgesics at launch.
Contact Us
Algomedix, Inc.
16212 Bothell-Everett Highway
Suite F280
Mill Creek, WA 98012
Direct: 425-379-7900
[Called this number. A man picked up the phone saying this was Algomedix]
www.algomedix.com/home.html
